Edwards Lifesciences Corporation (EW) has been generating mixed news with its diverse updates. While Evercore ISI has raised its price target from $69 to $75, the stock has reportedly underperformed against competitors on certain days. EW’s share price crossed above the 200-day moving average, drawing attention to its stock performance. Conversely, the corporation is also subjected to investor alerts and a class action lawsuit because of substantial shareholder losses. Despite such setbacks, speculation about EW’s potential as a cheap healthcare stock to buy heading into 2025 persists. The focus also falls on EW's strong growth seen in TMTT sales in the Q3 2024 earnings call. Amid reports of its stock plummeting and legal issues, EW showcased a 19.4% rise since the last earnings report. It was further announced that EW is selling its Critical Care product group to BD for $4.2 Billion, which might influence its financial outlook. Despite facing setback in revenue that missed expectations, EW followed it up by expanding its structural heart portfolio with acquisitions of JenaValve and Endotronix.
Edwards Lifesciences Corp EW News Analytics from Tue, 30 Apr 2024 07:00:00 GMT to Fri, 03 Jan 2025 11:46:31 GMT -
Rating -3
- Innovation 2
- Information 6
- Rumor -6
